Fundraising FoxBreakout Labs — 2020 Investments
1 investments dated 2020 · listed companies and verified rows first · show all
Glyscendglyscend.comJun 2020 · $20.5M
Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity.
BiotechDeep TechDigital HealthHealthtechLongevityBaltimore, US
Ashish Nimgaonkar(Executive Officer, Director)Dennis McWilliams(Director)inCasey Cunningham(Director)Leighton Read(Director)inBob Soh(Director)in
Co-investorsBrandon BioCatalystBrandon Capital Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.